Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
R&D to Revenue
446.59%
Quarterly · Period ending:
LCTX R&D to Revenue
Latest reported446.59%period ending
Latest reported446.59%period ending
LCTX Quarterly R&D/Revenue (0.00% → 446.59%)
Latest values, visible window
High-resolution chart · PNG
LCTX r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 1,808.8457% | |
| 1,694.1184% | |
| 1,287.3235% | |
| 0% | |
| 0% | |
| 0% | |
| 2,934.7227% | |
| 2,000% | |
| 183.3333% | |
| 175% | |
| 900% | |
| 150% | |
| 900% | |
| 180% | |
| 700% | |
| 0% | |
| 400% | |
| 500% | |
| 400% | |
| 0% | |
| 0% | |
| 0% | |
| 200% | |
| 0% | |
| 400% | |
| 500% | |
| 300% | |
| 0% | |
| 100% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |